Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Assets Average (2016 - 2025)

Historic Assets Average for Ani Pharmaceuticals (ANIP) over the last 16 years, with Q3 2025 value amounting to $1.4 billion.

  • Ani Pharmaceuticals' Assets Average rose 2459.2% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 2459.2%. This contributed to the annual value of $1.1 billion for FY2024, which is 3145.73% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Assets Average stood at $1.4 billion, which was up 2459.2% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Assets Average peaked at $1.4 billion during Q3 2025, and registered a low of $462.5 million during Q1 2021.
  • Over the past 5 years, Ani Pharmaceuticals' median Assets Average value was $812.3 million (recorded in 2023), while the average stood at $872.5 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Assets Average plummeted by 148.96% in 2021, and later skyrocketed by 6393.4% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Assets Average (Quarter) stood at $621.0 million in 2021, then rose by 20.7% to $749.6 million in 2022, then rose by 19.69% to $897.2 million in 2023, then surged by 43.29% to $1.3 billion in 2024, then grew by 7.0% to $1.4 billion in 2025.
  • Its Assets Average was $1.4 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.3 billion in Q1 2025.